Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Huanwen, Wu ^a   Zhiyong, Liang ^a   Xiaohua, Shi ^a   Xinyu, Ren ^a   Kai, Wang ^a   Tonghua, Liu ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE RELATED NON KINASE; GEMCITABINE; LAMININ; PHOSPHOTRANSFERASE; PROTEIN BAD; PROTEIN KINASE B; SERINE; SURVIVIN; TYROSINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; PRIMER DNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SPECIFICITY; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; DRUG RESISTANCE; ENZYMOLOGY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; PANCREAS TUMOR; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DEOXYCYTIDINE; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; LAMININ; PANCREATIC NEOPLASMS; PHOSPHORYLATION; RNA INTERFERENCE;

EID: 74549213069     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-125     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96. 10.3322/CA.2007.0010, 18287387.
2. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. Lancet 2004, 363:1049-57. 10.1016/S0140-6736(04)15841-8, 15051286.
3. von Wichert G, Seufferlein T, Adler G. Palliative treatment of pancreatic cancer. J Dig Dis 2008, 9:1-7. 10.1111/j.1443-9573.2007.00314.x, 18251787.
4. O'Reilly EM, Abou-Alfa GK. Cytotoxic therapy for advanced pancreatic adenocarcinoma. Semin Oncol 2007, 34:347-53. 10.1053/j.seminoncol.2007.05.009, 17674963.
5. Xiong HQ, Carr K, Abbruzzese JL. Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions. Drugs 2006, 66:1059-72. 10.2165/00003495-200666080-00003, 16789792.
6. Burris H, Rocha-Lima C. New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways. Oncologist 2008, 13:289-98. 10.1634/theoncologist.2007-0134, 18378539.
7. Kleespies A, Jauch KW, Bruns CJ. Tyrosine kinase inhibitors and gemcitabine: new treatment options in pancreatic cancer?. Drug Resist Updat 2006, 9:1-18. 10.1016/j.drup.2006.02.002, 16621676.
8. Danovi SA, Wong HH, Lemoine NR. argeted therapies for pancreatic cancer. Br Med Bull 2008, 87:T97-130.
9. Ko AH. Future strategies for targeted therapies and tailored patient management in pancreatic cancer. Semin Oncol 2007, 34:354-64. 10.1053/j.seminoncol.2007.05.002, 17674964.
10. Borja-Cacho D, Jensen EH, Saluja AK, Buchsbaum DJ, Vickers SM. Molecular targeted therapies for pancreatic cancer. Am J Surg 2008, 196:430-41. 10.1016/j.amjsurg.2008.04.009, 2570700, 18718222.
11. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-6. 10.1200/JCO.2006.07.9525, 17452677.
12. de Heer P, Koudijs MM, Velde CJ, Aalbers RI, Tollenaar RA, Putter H, Morreau J, Water B, Kuppen PJ. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation. Eur J Surg Oncol 2008, 34:1253-61.
13. Chatzizacharias NA, Kouraklis GP, Theocharis SE. Clinical significance of FAK expression in human neoplasia. Histol Histopathol 2008, 23:629-50.
14. van Nimwegen MJ, Water B. Focal adhesion kinase: a potential target in cancer therapy. Biochem Pharmacol 2007, 73:597-609. 10.1016/j.bcp.2006.08.011, 16997283.
15. Halder J, Kamat AA, Landen CN, Han LY, Lutgendorf SK, Lin YG, Merritt WM, Jennings NB, Chavez-Reyes A, Coleman RL, et al. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res 2006, 12:4916-24. 10.1158/1078-0432.CCR-06-0021, 16914580.
16. Smith CS, Golubovskaya VM, Peck E, Xu LH, Monia BP, Yang X, Cance WG. Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines. Melanoma Res 2005, 15:357-62. 10.1097/00008390-200510000-00003, 16179862.
17. Furuyama K, Doi R, Mori T, Toyoda E, Toyoda E, Ito D, Kami K, Koizumi M, Kida A, Kawaguchi Y, Fujimoto K. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J Surg 2006, 30:219-26. 10.1007/s00268-005-0165-z, 16425085.
18. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005, 5:505-15. 10.1038/nrc1647, 16069815.
19. Richardson A, Parsons T. A mechanism for regulation of the adhesion-associated prote in tyrosine kinase pp125FAK. Nature 1996, 380:538-40. 10.1038/380538a0, 8606775.
20. Walker HA, Whitelock JM, Garl PJ, Nemenoff RA, Stenmark KR, Weiser-Evans MC. Perlecan up-regulation of FRNK suppresses smooth muscle cell proliferation via inhibition of FAK signaling. Mol Biol Cell 2003, 14:1941-52. 10.1091/mbc.E02-08-0508, 165088, 12802066.
21. Li S, Hua ZC. FAK expression regulation and therapeutic potential. Adv Cancer Res 2008, 101:45-61. 10.1016/S0065-230X(08)00403-X, 19055942.
22. Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parson JT. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem 2007, 282:14845-52. 10.1074/jbc.M606695200, 17395594.
23. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-67.
24. Cordes N. Integrin-mediated cell-matrix interactions for prosurvival and antiapoptotic signaling after genotoxic injury. Cancer Lett 2006, 242:11-9. 10.1016/j.canlet.2005.12.004, 16448744.
25. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas 2004, 28:38-44. 10.1097/00006676-200401000-00006, 14707728.
26. Hodkinson PS, Elliott T, Wong WS, Rintoul RC, Mackinnon AC, Haslett C, T S. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ 2006, 13:1776-88. 10.1038/sj.cdd.4401849, 16410797.
27. Shi XH, Liang ZY, Ren XY, Liu TH. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo. Cancer Gene Ther 2009, 16:227-36.
28. Ricci MS, Zong WX. Chemotherapeutic approaches for targeting cell death pathways. Oncologist 2006, 11:342-57. 10.1634/theoncologist.11-4-342, 16614230.
29. Xu ZW, Friess H, Buchler MW, Solioz M. Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 2002, 49:504-10. 10.1007/s00280-002-0435-5, 12107556.
30. Shi X, Liu S, Kleeff J, Friess H, Buchler MW. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 2002, 62:354-62. 10.1159/000065068, 12138244.
31. Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y, Adachi K, Tasaka K, Kanzaki T, Murata Y. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000, 60:5988-94.
32. Liu WS, Yan HJ, Qin RY, Liu WS, Yan HJ, Qin RY. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 2009, 54:89-96. 10.1007/s10620-008-0329-4, 18594980.
33. Reddig PJ, Juliano RL. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 2005, 24:425-439. 10.1007/s10555-005-5134-3, 16258730.
34. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity. Biochem Biophys Res Commun 2003, 311:786-92. 10.1016/j.bbrc.2003.10.060, 14623342.
35. Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci 2003, 116:1409-16. 10.1242/jcs.00373, 12640026.
36. Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol 2005, 6:56-68. 10.1038/nrm1549, 15688067.
37. van Nimwegen MJ, Huigsloot M, Camier A, Tijdens IB, Water B. Focal adhesion kinase and protein kinase B cooperate to suppress doxorubicin-induced apoptosis of breast tumor cells. Mol Pharmacol 2006, 70:1330-9. 10.1124/mol.106.026195, 16825486.
38. Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res 2008, 14:627-63. 10.1158/1078-0432.CCR-07-2220, 18245520.
39. Jones ML, Shawe-Taylor AJ, Williams CM, Poole. Characterization of a novel focal adhesion kinase inhibitor in human platelets. Biochem Biophys Res Commun 2009, 389:198-203. 10.1016/j.bbrc.2009.08.132, 19716803.
40. Golubovskaya VM, Nyberg C, Zheng M, Kweh F, Magis A, Ostrov D, Cance WG. A small molecule inhibitor, 1, 2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth. J Med Chem 2008, 51:7405-16. 10.1021/jm800483v, 2662449, 18989950.
41. Shain KH, Dalton WS. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 2001, 1:69-78.
42. Lohr M, Trautmann B, Gottler M, Peters S, Zauner I, Maier A, Kloppel G, Liebe S, Kreuser ED. Expression and function of receptors for extracellular matrix proteins in human ductal adenocarcinomas of the pancreas. Pancreas 1996, 12:248-59.
43. Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, Johnson CD, Benyon RC, Iredale JP. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin Cancer Res 2004, 10:7427-37. 10.1158/1078-0432.CCR-03-0825, 15534120.
44. Fong YC, Liu SC, Huang CY, Li TM, Hsu SF, Kao ST, Tsai FJ, Chen WC, Chen CY, Tang CH. Osteopontin increases lung cancer cells migration via activation of the alphavbeta3 integrin/FAK/Akt and NF-kappaB-dependent pathway. Lung Cancer 2009, 64:263-70. 10.1016/j.lungcan.2008.09.003, 18996613.
45. Bouchard V, Harnois C, Demers MJ, Vallee K, Gagne D, Fujita N, Tsuruo T, Vezina A, Beaulieu JF, Cote A, Vachon PH. B1 integrin/Fak/Src signaling in intestinal epithelial crypt cell survival: integration of complex regulatory mechanisms. Apoptosis 2008, 13:531-42. 10.1007/s10495-008-0192-y, 18322799.
46. Bouchard V, Demers MJ, Thibodeau S, Laquerre V, Fujita N, Tsuruo T, Beaulieu JF, Gauthier R, Vezina A, Villeneuve L, Vachon PH. Fak/Src signaling in human intestinal epithelial cell survival and anoikis: differentiation state-specific uncoupling with the PI3-K/Akt-1 and MEK/Erk pathways. J Cell Physiol 2007, 212:717-28. 10.1002/jcp.21096, 17443665.
47. Liao CH, Sang S, Ho CT, Lin JK. Garcinol modulates tyrosine phosphorylation of FAK and subsequently induces apoptosis through down-regulation of Src, ERK, and Akt survival signaling in human colon cancer cells. J Cell Biochem 2005, 96:155-69. 10.1002/jcb.20540, 16052481.
48. Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 2005, 65:8423-32. 10.1158/0008-5472.CAN-05-0058, 16166321.
49. Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Murata Y. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem 2002, 277:33490-500. 10.1074/jbc.M204042200, 12087097.